Notice of Allowability	Application No.	Applicant(s)
	08/637,752	KERN ET AL.
	Examiner	Art Unit
	Mary E. Mosher, Ph.D.	1648
The MAILING DATE of this communication apperation apperation being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313 1. This communication is responsive to 10/28/2004. 2. The allowed claim(s) is/are 12,13 and 17-21. 3. The drawings filed on 02 May 1996 are accepted by the Extended All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have	ears on the cover sheet with to (OR REMAINS) CLOSED in this or other appropriate communication is subjusted and MPEP 1308. This application is subjusted and MPEP 1308. The caminer. The been received. The been received in Application New York (1998) (he correspondence addresss application. If not included ation will be mailed in due course. THIS ect to withdrawal from issue at the initiative included a
3. ☑ Copies of the certified copies of the priority doc International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of the priority document of the priority document.	of this communication to file a r	
noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	ENT of this application. itted. Note the attached EXAMII	NER'S AMENDMENT or NOTICE OF
 CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the 	t be submitted. on's Patent Drawing Review (F Amendment / Comment or in t	PTO-948) attached the Office action of
 DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F 	sit of BIOLOGICAL MATERI. FOR THE DEPOSIT OF BIOLO	AL must be submitted. Note the GICAL MATERIAL.
Attachment(s)		
1. ☐ Notice of References Cited (PTO-892)	5. Notice of Inform	nal Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6.	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date	8), 7. Examiner's Ame	endment/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ⊠ Examiner's Stat 9. ☐ Other	rement of Reasons for Allowance

Art Unit: 1648

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

On reconsideration, the rejection based on Shenk et al 6489162 is withdrawn. Applicant has amended the claims to state that the monoclonal antibody is capable of detecting AAV2 capsid or capsid protein in an ELIZA assay, immunofluoresence, or Western blotting. The examiner cannot determine whether or not the antibody of Shenk inherently possessed the recited characteristics. While it does seem probable that an antibody which immunoprecipitates a capsid protein would recognize the protein in one of the assays, the examiner has been unable to provide any additional evidence regarding the characteristics of the specific antibody disclosed by Shenk. While it is common in this situation to cite In re Best 195 USPQ 430 (CCPA 1977) and shift the burden to the applicant to distinguish the old product from the claimed product, this approach presupposes that the old product is enabled. The disclosure of a monoclonal antibody in Shenk does not permit one skilled in the art to reproduce that specific monoclonal antibody. Therefore Shenk does not meet the standard required for anticipation. In regard to obviousness, secondary considerations must be considered. It might have been routine to make a monoclonal antibody similar to Shenk's, however the prior art provides no strong motivation to do so. In contrast, applicant has disclosed an unexpected association between AAV2 infection and spontaneous abortion and provided a new and unexpected diagnostic utility for anti-AAV2 monoclonal antibodies. When the new and unexpected use is weighed against the weak motivation in the prior

Art Unit: 1648

art, the balance tips in applicant's favor. Therefore both alternative rejections under 102(e) and 103 are withdrawn.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. Mosher, Ph.D. whose telephone number is 571-272-0906. The examiner can normally be reached on M-T and alternate F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

GROUP 1800-1600